Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — Oncocyte — Investor Presentation (June 2021)
22 slides from Insight Molecular Diagnostics's investor presentation, Jun 24, 2021
Slide 1: A Treatment Stratification Test for Early-Stage NSCLC
i A Treatment Stratification Test for Early-Stage NSCLC MONCOCYTE KONCOCYTE
Slide 2: Forward Looking Statement
Forward Looking Statement ‘Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include tho
Slide 3: Mission Statement
Mission Statement Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer.
Slide 4: Oncocyte has Tremendous Organizational Velocity
Oncocyte has Tremendous Organizational Velocity Significant Accomplishments Over Past 12 Months and remainder of 2021 aceay Viideson 2020 ONCOCYTE
Slide 5: Oncocyte's Determa Platform Strategy
Oncocyte’s Determa Platform Strategy We are now in a solid position to be the only company delivering the entire continuum Diagnosis of Cancer ‘Treatment Decision Patient Monitoring Does patient have Should 1 give Should give Should Tove Is the therapy Ie the cancer ‘cancer? adjuvant chemo? targeted
Slide 6: Solid Pipeline Targeting a Large Served Available Market is On Track!
Solid Pipeline Targeting a Large Served Available Market is On Track! Determal0 and DetermaTx — Ginical Launch 221 IN Reatoas > 10 ongaeg wai es ‘oder 42021 even peering 2122 Ghbal TAM $58 DetermaCNI— RU0 Launch 2121 DetermaMx— R tn Dendopment Selang en rok ae “ONCOCYTE
Slide 7: DetermaRx Update
DetermaRx Update Proprietary predictive test for early-stage lung cancer ONCOCYTE
Slide 8: DetermaIO Update
DetermalO Update Precision Diagnostic For Immunotherapy Decisions ONCOCYTE
Slide 9: DetermaIO Addresses Important Unmet Need
DETERMABD) Addresses Important Unmet Need There is a need for an effective clinical biomarker for IO therapy to improve response and decrease cost of care... DETERMAD® delivers on both upto 750,000 Patients are eligible for 10 treatment/testing annually ~$3B ws ony) Annual Addressable Testing Market
Slide 10: DetermaIO Derived from a Well-Published Molecular Classifier
DetermalIO Derived from a Well-Pub! Molecular Classifier 2011- Lehmann ef a. published a 2188 gene molecular subclassification system for ‘TNBC tumors based on gene expression patterns 2016 - Ring et a/. reduced the classifier to 101 genes 2016 - Ring ef af. and Lehmann ef a/, noted that the IM (TIL
Slide 11: DetermaIO: A Precision Diagnostic to Determine Sensitivity to IO Therapies
DETERMAS” A Precision Diagnostic to Determine Sensitivity to IO Therapies Pes ene sicaion | Patients likely to p p ? RNA Expression J respond to current a's Soe tM Beg compe mt nd pet Crete] eC 6 Sess ee ‘opportunities DetermalO measures three distinct components of the tumor micro-environment (ME)
Slide 12: Why Do Such a Small Percentage of Tumors Respond to Immune Mono-Therapy?
Why Do Such a Small Percentage of Tumors Respond to Immune Mono-Therapy? Understanding the importance of the Entire Tumor Micro-Environment ae 2 [las-40% HoT > - i — ions penal roa, p gor a Ss 7m > <> oo re Sees . fanantic — ‘oenegen = — = ee oes = : — e i = es ——— : e == ae eee ‘Tumor selection / ‘
Slide 13: DetermaIO Qualifies More Patients for ICI treatment
DETERMA®D” Qualifies More Patients for ICI treatment TNBC MD Anderson Phase I: DetermalO- sgepacees itive patients are 4x more likely to NSCLC community setting: Assessment of TME clearly separates poss . . responders vs non-responders to Immune Checkpoint Inhibitors (ICI) respond than DetermalO-neg
Slide 14: AACR 2021 IMvigor210 Results Revealed Significant Association with Atezo Response
AACR 2021 IMvigor210 Results Revealed Significant Association with Atezo Response vs PD-L1 and TMB 27 Gene Predictor e4 ~ — 27cene 10-Positve = 2 —_27cene 1o-Negative me So Initial Results: 5 6 + DetermalO (27 Gene 10") Positivity was significantly ae 41% Pos associated with response to Atezo 2 + De
Slide 15: ASCO 2021 Renal Carcinoma Results Revealed Significant Predictive Value for ICI Response
ASCO 2021 Renal Carcinoma Results Revealed Significant Predictive Value for ICI Response 15 DetermalO continues to deliver predictive response data without retraining our algorithm vs TMB which is varies across tumor types TCGA data confirms same algorithm and threshold M2Gen RNAseq dataset demonstr
Slide 16: DetermaIO Predicts Response Across Solid Tumors
DETERMABD) Predicts Response Across Solid Tumors DetermaIO Data Summary To-Date: + Proven predictor of response in all indications tested to date (NSCLC, TNBC, Bladder, Renal), without changes to algorithm Applicable to both PD-1 and PD-L1 inhibitors and shown to work with all ICs tested to date (pe
Slide 17: The Chronix Acquisition
The Chronix Acquisition Our Entry Into Blood Based Monitoring “ONCOCYTE
Slide 18: Attractive market— TAM of $15B
Attractive market— TAM of $15B* Clear need to monitor: Pharma opportunity ‘Tumor response is variable and by identifying non-responders early in trials early decision to change therapy saves lives and healthcare costs, t % Market multiple expansion being seen by players claiming their potential in m
Slide 19: DetermaCNI Clinical Validation To Date
DetermaCNI Clinical Validation To Date Papers published with CNI results Rae Cancer types Methods used bail gs Renal, pancreatic, NGS to analyze CNV ~ 3 6 5 melanoma, lung, Published detection colon, breast, head, at < 0.1% of tumor derived neck, prostate cfDNA in plasma MUNRO NCC LAO NE Turner Colt
Slide 20: CNI Delivers Critical Answers Before Tumor Informed Monitoring
CNI Delivers Critical Answers Before Tumor Informed Takes First Baseline Blood Draw Monitoring Assa) Tumor Block Genome or ‘Custom NGS Personalized assay Ordered From > Exome ——> assay Development ——> deployed ‘Start Patient Monitoring Original Eatpiony for monitoring Final Patient Ss 1 For Progress
Slide 21: Oncocyte Growth Drivers
Oncocyte Growth Drivers Strategic Milestones Accelerate Enterprise Value 1H 2021 presentation a M0 REGH pines hsrma soma 2022 ts overage dcton ORE to tor Dharma as 2022/2023 pga og = om “ONCOCYTE
Slide 22: “ONCOCYTE
“ONCOCYTE